文献速递产科母胎医学

孕期抑郁、抗抑郁药使用与不良妊娠结局的个体参与数据荟萃分析

Associations Between Maternal Depression, Antidepressant Use During Pregnancy, and Adverse Pregnancy Outcomes: An Individual Participant Data Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2021-01-01

该个体参与数据荟萃分析纳入27个研究数据库共402375名女性,评估孕期抑郁症状及抗抑郁药使用与早产、低出生体重、小于胎龄儿和低Apgar评分的关联,发现抑郁本身与早产和低Apgar评分相关,SSRI使用可能独立关联早产和低Apgar评分。

要点

  • 孕期临床诊断抑郁者早产风险升高(OR 1.6,95%CI 1.2-2.1),未用抗抑郁药者亦升高(OR 2.2,95%CI 1.7-3.0)。
  • 临床诊断抑郁者低Apgar评分风险升高(OR 1.5,95%CI 1.3-1.7),未用药者未见此关联。
  • SSRI使用与早产相关(OR 1.6,95%CI 1.0-2.5;有抑郁症状或诊断者OR 1.9,95%CI 1.2-2.8)。

核心结论

  • 孕期抑郁症状或临床诊断抑郁与早产和低Apgar评分相关,即使未使用抗抑郁药。
  • SSRI可能独立关联早产和低Apgar评分。

研究设计与样本

  • 个体参与数据荟萃分析,纳入27个研究数据库共402375名女性,采用一阶段随机效应模型估计OR及95%CI。

主要发现

  • 孕期临床诊断抑郁者早产风险升高(OR 1.6,95%CI 1.2-2.1),未用抗抑郁药者亦升高(OR 2.2,95%CI 1.7-3.0)。
  • 临床诊断抑郁者低Apgar评分风险升高(OR 1.5,95%CI 1.3-1.7),未用抗抑郁药者未见此关联。
  • SSRI使用与早产相关(OR 1.6,95%CI 1.0-2.5;有抑郁症状或诊断者OR 1.9,95%CI 1.2-2.8)。
  • 有抑郁症状或诊断且使用抗抑郁药者低Apgar评分风险升高(OR 1.7,95%CI 1.1-2.8)。

临床怎么用

  • 孕期应关注抑郁症状和临床诊断抑郁对早产及低Apgar评分的影响,即使未用药也需监测。
  • 使用SSRI时需权衡早产和低Apgar评分的潜在风险,个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the associations of depressive symptoms and antidepressant use during pregnancy with the risks of preterm birth, low birth weight, small for gestational age (SGA), and low Apgar scores. DATA SOURCES: MEDLINE, EMBASE, ClinicalTrials.gov, and PsycINFO up to June 2016. METHODS OF STUDY SELECTION: Data were sought from studies examining associations of depression, depressive symptoms, or use of antidepressants during pregnancy with gestational age, birth weight, SGA, or Apgar scores. Authors shared the raw data of their studies for incorporation into this individual participant data meta-analysis. TABULATION, INTEGRATION, AND RESULTS: We performed one-stage random-effects meta-analyses to estimate odds ratios (ORs) with 95% CIs. The 215 eligible articles resulted in 402,375 women derived from 27 study databases. Increased risks were observed for preterm birth among women with a clinical diagnosis of depression during pregnancy irrespective of antidepressant use (OR 1.6, 95% CI 1.2-2.1) and among women with depression who did not use antidepressants (OR 2.2, 95% CI 1.7-3.0), as well as for low Apgar scores in the former (OR 1.5, 95% CI 1.3-1.7), but not the latter group. Selective serotonin reuptake inhibitor (SSRI) use was associated with preterm birth among women who used antidepressants with or without restriction to women with depressive symptoms or a diagnosis of depression (OR 1.6, 95% CI 1.0-2.5 and OR 1.9, 95% CI 1.2-2.8, respectively), as well as with low Apgar scores among women in the latter group (OR 1.7, 95% CI 1.1-2.8). CONCLUSION: Depressive symptoms or a clinical diagnosis of depression during pregnancy are associated with preterm birth and low Apgar scores, even without exposure to antidepressants. However, SSRIs may be independently associated with preterm birth and low Apgar scores. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42016035711.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vlenterie R, van Gelder MMHJ, Anderson HR, et al. Associations Between Maternal Depression, Antidepressant Use During Pregnancy, and Adverse Pregnancy Outcomes: An Individual Participant Data Meta-analysis. Obstet Gynecol. 2021. PMID: 34623076. doi:10.1097/AOG.0000000000004538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。